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Abstract 
 
Effective adoptive T cell therapy requires the ex-vivo generation of functional T lymphocytes with 
a long lifespan in-vivo. We evaluated in-vitro T cell expansion by artificial antigen presenting cells 
(aAPC) generated with activating (human anti-CD3), co-stimulating (human anti-CD28) and 
adhesion (human anti-LFA-1) monoclonal antibodies pre-clustered in microdomains (MDs) held by 
a liposome scaffold. The co-localization of T cell ligands in MDs and the targeting of an adhesion 
protein, increasing the efficiency of immunological synapse formations, represent the novelties of 
our system. These aAPCs allowed increased expansion of polyclonal CD4+ and CD8+ T cells and 
of tumor antigen-specific CD8+ T cells compared to anti-CD28- and anti-CD3-coated microbeads 
and to immobilized anti-CD3. These aAPCs allowed the generation of T cells displaying an 
immunophenotype consistent with long-term in-vivo persistence, without increasing the frequency 
of regulatory T cells. Finally, our aAPCs proved to be suitable for large scale T cell expansion 
required in immunotherapy trials. 
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Introduction 
 
The in vitro activation and expansion of antigen-specific T cells for therapeutic purposes has 
yielded impressive results in the context of prophylaxis and treatment of virus-associated infection 
and disease post-transplant1, 2. These successes prompted the extension of this method for the 
treatment of tumors in immunocompetent individuals3, 4, given the finding that antitumor specific T 
lymphocytes exist in cancer patients5-7, even if they are not able to overcome tumor immune escape 
mechanisms and to react efficiently against the tumor.  
 
For clinical purposes, the use of natural antigen presenting cells (nAPCs), usually dendritic cells 
(DCs) or virally infected B cells, to activate and expand T cells for adoptive immunotherapy has 
been studied8, but still poses a lot of challenges. In particular, they require several months to 
produce sufficient numbers of T cells that may be a limiting factor in the setting of malignancy. 
Moreover, after a long-term ex-vivo expansion, T cells are expected to have limited replicative 
capacity and persistence upon infusion into patients. Finally, the use of nAPC is limited by the 
difficulties in standardize protocols for their in-vitro generation, which, being highly sensitive to the 
culture conditions, is hardly reproducible 9, and by the prerequisite for their application only in an 
autologous setting.  
 
These evidences led to the production of artificial systems that express relevant molecules for T cell 
expansion. In this way, the functional activity of artificial APC can be modulated modifying the 
composition of the expressed molecules. Although several artificial systems have been produced10-
21, only the following systems are suitable for clinical use being generated under “Good 
Manufacturing Practice” (GMP): immunomagnetic beads coated with anti-CD3 and anti-CD28 
monoclonal antibodies (mAbs)22, 23 and anti-CD3 mAb immobilized on well bottom of culture 
plates. Even if these technologies are able to efficiently support the expansion of CD4+ T cells24, the 
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long-term growth of purified CD8+ T cells 25 is hampered. More likely, the reason consists in a not 
efficient interaction of these systems with T cells26, 27, since they are not supplied with a fluid 
membrane, which makes it impossible for ligands to cluster and efficiently activate T cells.  
 
The present work has been aimed at engineering an aAPC-based system with the properties of a 
fluid cellular membrane and the flexibility derived from an artificial structure, which can be 
properly tailored at the purpose. A stable interaction with APC for T cell activation is dependent not 
only on the absolute affinity between the T cell receptor (TCR) and its ligand but also on the 
relative density of relevant molecules at the interaction site. Furthermore, it has been recently 
shown that preclustering of MHC-peptide complexes in membrane MDs on the APC surface affects 
the efficiency of immune synapse formation and the related T cell activation28, 29. For these reasons, 
starting from aAPCs manufactured by Albani in which a liposomal formulation is loaded with class 
II HLA molecule-peptide complexes associated with costimulatory molecules, we modified aAPC 
by adding anti-CD3, instead of HLA molecule, and anti-LFA-1 adhesion molecule on MDs in 
lipidic bilayer to allow an efficient aAPC-T cell interaction. 
 
We demonstrated that these aAPCs are able to expand more efficiently, compared to the other 
commercial artificial techniques, both viable and functional polyclonal T cells and antigen specific 
cytotoxic T lymphocytes (CTLs) with immunophenotypic characteristics that suggest a potential 
long-term persistence in vivo.  
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Materials and Methods 
Generation of aAPC  
For the preparation of aAPCs, the materials used by Albani et al. for the identification of rare 
antigen-specific T cells in autoimmune disorders30-32 was made suitable for ex-vivo T cell activation 
and expansion with appropriate modifications. The resulting aAPCs consisted in a scaffold made of 
GM1 enriched-liposomes, which anchor microdomains (MDs) where mouse antihuman CD3, CD28 
(BD PharMingen, San Diego, California) and LFA1 (Biodesign, Saco, Maine) triggering mAbs 
have been preclustered (Figure1A). At this end, biotinylated anti-CD3, anti-CD28 and anti-LFA1 
mAbs were combined with biotinylated cholera toxin B (CTB; Sigma-Aldrich Inc.) in a 3:1 molar 
ratio for 5’ at room temperature (RT), as previously described30. Therefore, neutravidin (NA; Pierce 
Biotechnology, Rockford, Illinois) was added at a ratio of 1 mol of NA per 4 biotinylated moieties. 
After 15’ of incubation at RT, the ganglioside GM1 enriched liposomes (gently provided by Dompè 
Biotec Spa, L’Aquila, Italy) were added. Liposomes were formed by detergent removal for 72 h 
through dialysis at 4°C against PBS in a 10K Slide A Lyzer (Pierce Biotechnology, Rockford IL). 
After 90’ of incubation while mixing, the aAPC solution was washed in PBS at 14000 rpm for 10’. 
The pellet with aAPCs was resuspended in culture medium and used for T cell expansion. As 
controls, only the liposomial formulation (liposome alone) or the biotinylated mAbs on neutravidin 
rafts without liposomes (MD alone) were used in T cell cultures in the same conditions of complete 
aAPCs (Figure 2). In order to corroborate the choice of the association of those three mAbs on 
aAPCs to achieve the best T cell expansion, initial experiments were performed using aAPC whose 
MDs contained only one type (anti-CD3 or anti-CD28 or anti-LFA1) or two types (anti-CD3 and 
anti-CD28, anti-CD28 and anti-LFA1, anti-CD3 and anti-LFA1) of biotinylatd mAbs in 
comparison. Briefly, CFSE (CFDA, SE; Molecular Probe Inc. Eugene, Oregon) stained PBMCs 
from healthy donors were stimulated with anti-CD3/-CD28/-LFA1 aAPCs, or anti-CD3/-CD28 
aAPCs or anti-CD3/LFA1 aAPCs or anti-CD28/-LFA1 or anti-CD3 aAPCs or anti-CD28 aAPCs or 
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anti-LFA1 aAPCs where mAbs were added at serial dilutions (1-1/64). CFSE dilution was assayed 
after 4, 7 and 10 days by FACSCalibur device and results were analyzed with CellQuest software 
(Becton Dickinson). 
 
Human cells and culture conditions 
Two sources of T cells were tested for the expansion: i. CD3+ lymphocytes, negatively isolated 
from peripheral blood mononuclear cells (PBMCs) obtained from the heparinized blood of healthy 
donors after Ficoll-Hypaque density gradient separation, using Pan T cell isolation kit with a 
MiniMACS device (Miltenyi Biotech, Gladbach, Germany), according to the manufacturer’s 
protocol; ii. Lymphocytes from melanoma associated lymph nodes were cultured for 2 weeks with 
HLA-A*0201+ T2 loaded with 10 μg/ml of Melan-A/MART-1 27-35 (modified sequence 27–35: 
ELAGIGILTV; PRIMM s.r.l., San Raffaele Biomedical Park, Milan Italy)33, 34 as described35. 
Frequency of tetramer+ T cells in the CD8+ fraction was analyzed before and at the end of culture. T 
cells were cultured at a concentration of 0.2 x 106 cells/ml in a 96 flat-bottom well plate with 250 
μl/well of RPMI 1640 (Cambrex, Verviers, Belgium) containing 10% human serum (HS), 1% 
PenStrep (Cambrex, Verviers, Belgium), 1% Glutamine (Cambrex, Verviers, Belgium) and 1% 
Hepes buffer (Cambrex, Verviers, Belgium). T cell expansions were performed with a single 
administration of aAPCs or immunomagnetic beads (Figure 1B) coated with mouse antihuman CD3 
and CD28 mAbs (Dynabeads CD3/CD28 T cell Expander, Dynal Biotech ASA, Oslo, Norway) 
according to the manufacturer’s instruction, or mouse antihuman CD3 mAb (Functional grade 
purified anti-hCD3, OKT3 clone, eBioscience, San Diego, California) immobilized on well bottom. 
Anti-CD3 was cross-linked (Figure 1C) to the well bottom of 96 flat bottom well plates precoated 
with anti-mouse IgG (whole molecule, SIGMA). Briefly, the plates were incubated with anti-mouse 
IgG at10 μg/ml in PBS (Cambrex, Verviers, Belgium) at 4°C, over night. The day after, anti-mouse 
IgG was removed from the plates and the wells have been washed three times with PBS. Then, anti-
CD3 was added at 0.5 μg/ml of RPMI 1640 (50 μl/well) and the plates were incubated for 45’ at 
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4°C. The incubation was stopped by blocking the plates with 20% HS supplemented RPMI 1640 
(50 μl/well).  
These cultures were carried on with the following combination of γ-chain cytokines accordingly to 
previous results36: i. low dose (LD) rhIL-2 (300U/ml, Proleukin, Chiron, Emeryville, California), ii. 
rhIL-15 (Peprotech Inc., Rocky Hill, New Jersey) 10 ng/ml, iii. high dose (HD) rhIL-2 (3000 U/ml) 
plus rhIL-15 10 ng/ml. Complete culture medium with cytokines was changed every 2 days during 
the 14 day-expansion with the artificial systems. 
The aAPC stimulation: T cell ratio was reduced by diminishing mAb dose for the generation of 
aAPCs or by increasing the starting T cell amount in culture with aAPCs produced as previously 
described. In the first case, the biotinylated mAbs were added at 1/10 or 1/100 of the standard dose, 
resulting with biotinylated cholera toxin B and NA in 3/10 or 3/100: 1 molar ratio respectively. 
These aAPCs were used for 14 day-expansion of 0.05 x 106 CD3+ purified T cells in association 
with HD IL-2 and IL-15 and they were compared to the standard ones in the same culture condition. 
In addition, standard aAPCs were tested for the expansion of 10 or 100 fold increase number of 
starting T cell. Briefly, 0.5 x 106 or 5 x 106 CD3+ purified T cells were cultured in 1 or 4 ml of 
culture medium in 48 or 12 well plates respectively with standard aAPCs in the presence of HD IL-
2 plus IL-15. Culture medium with cytokines was changed every 2 days during the 14 day- 
expansions. 
 
Flow cytometric analysis 
Flow cytometric analysis of expanded T cells was performed on a FACSCalibur using the 
CellQuest software (Becton Dickinson). Data were subsequently analyzed using FlowJo software. T 
cell maturation status and activation phenotype were evaluated by multiparametric analyses using 
the following mouse-antihuman mAbs and MHC tetramers in different combinations: FITC-labeled 
anti-CD62L (BD BioSciences, San Jose, California), FITC-labeled anti-CD3 (Miltenyi Biotech, 
Gladbach, Germany), PE-labeled anti-CD45RA (BD Pharmingen, San Diego, California), PE-
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labeled anti-CD4 (BD Biosciences, San Jose, California), PE-labeled anti-CD25 (Miltenyi Biotech, 
Gladbach, Germany) mAbs, PE-labeled tetramers of HLA-A 0201 containing Melan-A/MART-1 
peptide (Beckman Coulter Inc., Fullerton, California), PerCP-labeled anti-CD4, anti-CD69 and anti-
CD3, APC-labeled anti-CD8 and anti-CD4 (BD Biosciences, San Jose, California). Surface 
stainings were performed by incubating mAbs at 4°C for 30’. 
Regulatory T cell expansion was assayed by intracellular hFOXP3 staining using FITC-labeled anti-
human FOXP3 staining kit (eBioscience, San Diego, California) in association with PE-labeled 
anti-CD25, PerCP-labeled anti-CD8 and APC-labeled anti-CD4 surface mAbs, according to the 
manufacturer’s protocol. 
Apoptosis assay was performed staining with FITC-labeled annexin V and propidium iodide (rh 
Annexin V/FITC Kit, Bender MedSystem, Vienna, Austria), according to the manufacturer’s 
protocol. 
To detect intracellular perforin or granzyme B after 14 days from artificial stimulations, expanded T 
cells were permeabilized with Cytofix/Cytoperm (BD Biosciences, San Jose, California) and then 
stained with mouse-antihuman FITC–labeled anti-Perforin (BD Biosciences, San Jose, California), 
or PE–labeled anti-Granzyme B (CLB, Amsterdam, The Netherlands) in the presence of 
Perm/Wash solution (BD Biosciences, San Jose, California). Multiparametric analyses of perforin 
or granzyme B expression in T cell subsets, defined by anti-CD-3, anti-CD8 and anti-CCR7 
(mouse-antihuman APC-labeled CCR7 mAb, R&D systems, Minneapolis, Minnesota) mAb 
staining, were performed. 
 
Cytotoxic assay 
The cytotoxic activity of expanded specific MART-1 T cells was assessed through 51Cr-release 
assay using as target Melan-A/MART-127-35 (AAGIGILTV, PRIMM s.r.l., San Raffaele Biomedical 
Park, Milan Italy) pulsed lymphoblastoid cell line (LCL 9742). As negative controls, unpulsed-LCL 
or LCL pulsed with Influenza A (Flu) Matrix58-66 (GILGFVFTL, PRIMM s.r.l., San Raffaele 
N
at
ur
e 
Pr
ec
ed
in
gs
 : 
hd
l:1
01
01
/n
pr
e.
20
07
.1
25
0.
1 
: P
os
te
d 
24
 O
ct
 2
00
7
 9
Biomedical Park, Milan Italy) or HIV (ILKEPVHGV, PRIMM s.r.l., San Raffaele Biomedical Park, 
Milan Italy) were used. Sintetic peptides were ≥95% pure35. Results were expressed as follows: 
% Lysis = (experimental release (cpm) - spontaneous release (cpm))/ (maximum release   (cpm) - 
spontaneous release (cpm)) x 100, 
where spontaneous release was assessed by incubating target cells in the absence of effectors and 
maximum release was determined in the presence of 1% Nonidet P40 detergent (BDH Biochemical, 
Poole, UK). 
 
Statistical analysis 
Analysis of statistical significance were performed by using the Student’s t test at the two-sided 
0.05 significance level on Prism software (*: P≤ 0.05;**: P≤ 0.02; ***: P≤ 0.01). 
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Results 
aAPCs efficiently bind and expand human polyclonal T cells 
As shown in Figure 1, aAPCs consists of a scaffold made of GM1 enriched-liposomes, which 
anchor microdomains (MDs) of preclustered activating biotinylated mAbs (anti-CD3, anti-CD28, 
and anti-LFA1) through biotinylated CTB subunit and NA. The highest proliferation rate of selected 
polyclonal CD3+ T (mean purity 90±3%) cells was obtained combining all the three activating 
molecules on aAPCs (data not shown). In the following experiments aAPCs containing the mixture 
of all the three mAbs were tested in association with LD IL-2, or IL-15 or HDIL-2 plus IL-15 for 
their ability to expand in vitro human polyclonal CD3+ T cells. As controls, T cells were cultured 
with liposomes or with MDs alone. After 7 days from the stimulation, the greatest efficiency was 
observed when complete aAPC were associated to any cytokine combinations. However, after 2 
weeks, aAPCs combined with exogenous HD IL-2 plus IL-15 resulted in the greatest T cell fold 
increase that was statistically significant when compared to the other conditions (Figure 2; *: P≤ 
0.05; ***: P≤ 0.01).  
MDs alone provided a positive stimulus for T cell proliferation, since they consisted of the 
biotinylated activating molecules grouped on NA, but putting them into a lipidic membrane allowed 
their activity to be efficiently oriented, raising the final stimulus for T cell expansion. Liposomes 
alone did not provide expanding stimulation for T cell cultures (Figure 2).  
 
aAPC stimulation enhance survival of human polyclonal T cells 
Our aAPCs were compared with GMP systems (anti-CD3 and anti-CD28 coated immunomagnetic 
microbeads or immobilized anti-CD3) for the efficiency in expanding purified polyclonal CD3+ T 
cells. The cytokines reported above were added to T cell culture. Two weeks following the 
stimulation, the best methods resulted microbeads and aAPCs in combination with HD IL-2 plus 
IL-15 displaying comparable efficacy of polyclonal T cell expansion (Figure 3A). However, when 
apoptosis of expanded T cells was evaluated, aAPCs preserved the highest cell viability in culture 
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compared to the other artificial systems (Figure 3B). In the bead-stimulated culture, only the 46% of 
expanded T cells was viable (annexin V-/propidium iodide-), whereas 83% of T cells were still 
alive 14 days after the stimulation with aAPCs that in turn displayed the statistically highest 
expansion (Figure 3C). 
 
Immunophenotype of expanded polyclonal T cells 
Fourteen days after stimulation, T cells displayed a naïve/effector phenotype, with a still evident 
CD62L positivity and a high expression of the activation marker CD69, in all experimental 
conditions. In particular, bead and aAPC stimulated cells displayed an even higher expression of 
CD62L compared to immobilized anti-CD3 expanded lymphocytes. The expression of the homing 
adhesion molecule CD62L on the expanded T cells should confer to them the capability of 
trafficking through lymph nodes, where they could be involved in physiological responses and in 
the following memory development. On the other hand, the high expression of a marker associated 
with TCR engagement (CD69) suggests that such cells are acutely activated and could exert 
immediate effector functions upon in vivo re-infusion.  
In addition, when our aAPCs were used, CD8+ T cells were predominantly expanded, while CD4+ T 
cells were preserved at low level. On the contrary, anti-CD3/-CD28 microbead and immobilized 
anti-CD3 stimulation preferentially gave rise to CD4+ lymphocyte expansion (Figure 4A-B). 
Finally, the risk to expand also regulatory T cells was evaluated calculating their frequency in the 
culture of polyclonal T lymphocytes stimulated with the different artificial systems. Two weeks 
after the stimulation with aAPCs, the frequency of CD4+FoxP3+ T cells or of CD8+FoxP3+ T cells 
was statistically lower (Figure 4A-B). When regulatory T cells were analyzed, both CD25+ and 
CD25- FoxP3+ CD4+ were considered, given the recent evidence that FoxP3 expression can be 
found independent of the CD25 one37. 
By comparing the mean fluorescence intensity (MFI) of granzyme B staining on the differently 
expanded CD8+ or CD4+ T cells, our APCs resulted in the lowest up-regulation of granzyme B 
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expression among artificial stimulations tested (Figure 4C, left panel). Moreover, when our aAPCs 
were used, perforin expression was kept at the lowest level and was confined to a minimal fraction 
of expanded CD8+ or CD4+ T cells (Figure 4C, right panel). The reduced differentiating properties 
of our aAPCs were confirmed even analyzing the expression of perforin and granzyme B in the 
CCR7+ and CCR7- sub-populations in both CD4+ and CD8+ cell subsets (data not shown). These 
observations suggest that T cells expanded in the presence of our aAPCs are prone to kill, since they 
express granzyme B, but they require a further activation to do it, due to the limited induction of 
perforin expression following the in vitro stimulation. This phenotype is consistent with the high 
expression of CD62L and with the increased survival of T cells expanded with aAPC and further 
support the possibility that our method of T cell stimulation might generate T cells with prolonged 
lifespan in vivo and more likely able to persist in the memory compartment compared to the other 
artificial GMP systems. 
 
Specific cytotoxic activity of efficiently expanded T cells by aAPCs is preserved 
Since aAPCs rapidly activated and expanded polyclonal T lymphocytes, we have also tested aAPCs 
for the expansion of human anti-melanoma CTLs enriched for MART-1 specificity. MART-1 
loaded HLA-A*0201+ TAP-deficient T2 cell line was used as APCs for anti-MART-1 specific TAL 
expansion, isolated from melanoma involved lymph nodes. After two culture weeks with the 
cognate peptide, they were aspecifically stimulated with aAPCs or immobilized anti-CD3 or with 
anti-CD3/-CD28 microbeads and expanded for additional 14 days in the presence of HD IL-2 and 
IL-15. As shown in Figure 5A, the highest expansion was obtained using aAPCs. In addition, anti-
MART-1 CD8+T lymphocytes stimulated with aAPCs preserved the closest specific cytolytic 
activity to the anti-MART-1 CD8+ enriched T cell grown with MART-1 pulsed-T2 cell line (Figure 
5B). By contrast, while maintaining a highly pure anti-MART-1 CD8+ T cell population, the 
stimulation with the cognate antigen exhibited a limited expansion efficacy (Figure 5A-B). The 
aAPC trend in preferentially supporting the expansion of CD8+ T lymphocytes seen in polyclonal 
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setting could reflect aAPC capability to preserve the specific activity of expanded anti-MART-1 
specific CD8+ T cells that in turn might be responsible of the antitumor effect.  
Moreover, the viability of aAPC expanded anti-MART-1 CD8+ T cells was preserved even in this 
setting (Figure 5C). 
 
Immunophenotype of expanded anti-MART-1 CTLs  
The immunophenotype of CD4+ and CD8+ T cells generated during the expansion of anti-MART-1 
CTLs with aAPCs is shown Figure 6 that reported a representative FACScan analysis. The high 
positivity for CD62L expression in both CD8+ and the rare CD4+ T cells is consistent with in-vivo 
long-term persistence (Figure 6). On the other hand, the widespread expression of CD69 suggested 
that the stimulation of aAPCs could activate specific CTLs as efficiently as polyclonal T cells 
(Figure 6). In addition, after 14 culture days with aAPCs plus HD IL-2 and IL-15, the frequency of 
FoxP3+ regulatory T cells was not increased for both total CD8+ and anti-MART-1 specific CD8+ T 
cells, as well for the less frequent CD4+ T cells (Figure 6). 
 
Optimization of aAPC T cell expansion culture 
In order to allow the feasibility of the procedure on large–scale for clinical application, several 
experiments have been performed reducing the dose aAPC stimulation or increasing the 
concentration of T cells in cultures. Diminishing to 1/10 or 1/100 the dose of biotinylated mAbs 
added to the aAPC mixture did not saturate the MDs, present on the liposome scaffold in the same 
number, saturated of stimulating molecules. These systems were less efficient than standard aAPCs 
in expanding the same number of starting T cells (data not shown). The best results were achieved 
when starting T cell number was increased of 10 or 100 fold (Figure 7A). Moreover, the maturation 
status and the potential capability of in vivo persistence, on the basis of CD62L expression, are 
preserved even on large-scale (Figure 7B). In addition, at 1:10 aAPCs: T cell ratio, 10 billion of 
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antitumor T cells can be generated in a reduced volume with a limited cost, which makes this 
procedure suitable for clinical application (Figure 7C).  
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Discussion 
 
In this report we demonstrate the advantages in T cell expansion conferred by a fully artificial 
system capable of mimicking nAPC membrane reorganization during immune synapse formation. 
Our aAPCs exhibit high efficiency (1) in generating large numbers of T cells starting from 
polyclonal CD3+ T cells, (2) preserving the highest cell viability in culture compared to the other 
commercial artificial systems, (3) enriching the fraction of T cells expressing a central memory-
naïve phenotype, (4) without increasing the frequency of CD25high FoxP3+ regulatory T cells; (5) 
moreover they show a great activity in expanding functionally competent anti-MART-1 specific 
CD8+ T cells and (6) finally prove to be suitable for clinical application on large scale. 
 
To engineer our artificial system, we exploit the structure of the aAPCs developed by Albani S. et 
al.30-32 By simply substituting the HLA-peptide complexes, which originally covered one site on 
MDs, with the ubiquitous TCR triggering signal conferred by anti-CD3 mAb and by adding the 
most suitable molecules for a productive T cell activation, we obtain aAPCs capable to efficiently 
stimulate and expand T cells irrespective to their antigen-specificity. These aAPCs are provided 
with triggering mAbs, which mimic the function of activating, co-stimulatory and adhesion 
molecules, preclustered in MDs within a liposome mixture. Our aAPCs differ from the other 
acellular artificial systems for the presence of a fluid membrane that allows the free movement of 
the MDs and their effective orientation after T cell contact for the productive formation of 
immunological synapses. Moreover, the possibility to create in advance a first level of clusterisation 
by grouping the triggering molecules for T cell activation on MDs and the presence of the anti-
LFA-1 mAb among them, which acts as the most important adhesion molecule on nAPC (ICAM-1), 
represent the other advantages of our system. In fact, favoring a more stable interaction with T cells, 
these strategies increase the possibility of the immune synapse formation, the essential prerequisite 
for T cell activation. The aspecific but highly sensitive activity of our aAPCs could be useful for 
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anticancer immunotherapy, since it might be desirable to expand low avidity tumor specific T cells, 
in particular when tumor associated antigen are unknown. 
 
A single administration of our aAPCs to polyclonal CD3+ T cells cultured with HD IL-2 plus IL-15 
gives rise to the highest expansion of viable cells when compared to the other artificial commercial 
systems (anti-CD3/-CD28 microbeads and immobilized anti-CD3). The evidence that, after 14 days, 
aAPC cultured-polyclonal CD3+ T cells have a negligible amount of apoptotic and necrotic cells, 
further supporting the paraphysiologic stimulation performed by our aAPCs, is of great relevance in 
the practice of adoptive immunotherapy which include criopreservation and thawing of T cells, 
whose viability is strongly related with their capability to persist in vivo and with the possibility to 
generate a clinical response.  
 
Concurrently, a growing appreciation regarding lymphocyte characteristics that can impact on 
lymphocyte behavior in vivo is influencing the practice of ACT therapy. For instance, the discovery 
that the maturation status of CD8+ T lymphocytes determines their in vivo migration and 
persistence during an immune response38-42 indicates new avenues for manipulating T cell activity. 
These might include the alteration of in vitro T cell cultures to maintain a central memory 
phenotype39. Our work demonstrates that by associating aAPCs to HD IL-2 plus IL-15 it was 
possible to obtain the best expansion while generating T cells with a high expression of CD69, a 
marker associated with TCR engagement, and CD62L, a secondary lymphoid organ homing 
molecule. Moreover, our system was able to extensively arm expanded T cells with granzyme B, 
while reserving the capability to kill the target to a limited fraction of perforin+ T cells, suggesting 
that, 14 days after stimulation, T cells were not terminal differentiated. Together these evidences 
suggest that part of expanded cells are acutely activated and could exert immediate effector 
functions upon in vivo infusion, but other cells retaining the capability to traffic through lymph-
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nodes, showing a naïve-memory phenotype, could be stimulated in vivo and then persist in the 
memory compartment40.  
 
In addition, recent reports describing a requirement of CD4+ T cells for persistence of CD8+ T cells 
after an immune response underlines a potential role of CD4+ T cells in TIL cultures for ACT 
therapy 43-45. Since cancers are for the most part weakly immunogenic and develop over long period 
of time, the presence of CD4+ T cells after ex-vivo expansion may be crucial for the effectiveness of 
ACT. Our aAPCs, while preferentially sustain the expansion of CD8+ T cells, exhibit a good 
activity even on CD4+ T cells.  By contrast, the demonstration that CD4+CD25+ regulatory T cells 
suppress autoimmunity and might be potent inhibitors of antitumor effects in mice indicates a 
rationale for additional investigation on lymphodepleting conditioning for ACT therapy46, 47. For 
these reasons, we evaluated the frequencies of CD4+ and CD8+ regulatory T cells defined as FoxP3+ 
and CD25+ in expanded cultures, and we found that they were kept at the lowest level when aAPCs 
were used. By contrast, using the other two systems, the amount of regulatory T cells was increased. 
 
When aAPCs were assayed in pre-enriched MART-1 specific CD8+ T cell culture as aspecific 
stimulation, mimicking a possible program of anti-cancer immunotherapy, they highly efficiently 
generate the T cell population with the closest specific cytolytic activity to the same lymphocytes 
maintained in culture with MART-1 pulsed-T2, compared with antitumor CTLs expanded with 
microbeads or OKT3. Moreover, similarly to the expanded polyclonal T cell population, MART-1 
specific CD8+ T cells cultured with our aAPCs still exhibit a central memory-naïve phenotype 
associated with a high expression of CD69, with no increase in regulatory T cell frequencies. Thus, 
previously enriched antigen specific CD8+ T cells can be efficiently expanded with aAPCs without 
any limitations due to HLA compatibility.  
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Because T cell expansion with aAPCs can be achieved with high efficiency even starting from a 
larger amount of T cells in a reduced volume limiting the costs for large-scale applications, it is 
likely that this system could have therapeutic potential in clinical setting for patients with cancer 
and viral diseases. In particular, using aAPCs to expand aspecifically the full T cell population of 
cancer patients, we envisage the possibility to increase the frequency of TAA specific lymphocytes 
which are usually represented at low level in the immune repertoire even after their initial 
amplification by boosting in vivo with specific vaccination48,40. Moreover, in case of highly 
immunogenic tumors where TAAs are known and the related peptides available, it is possible to 
perform the aspecific expansion with aAPCs after the ex-vivo enrichment of antitumor specific 
CTLs using in vitro co-cultivation with autologous tumor cells49.  
 
N
at
ur
e 
Pr
ec
ed
in
gs
 : 
hd
l:1
01
01
/n
pr
e.
20
07
.1
25
0.
1 
: P
os
te
d 
24
 O
ct
 2
00
7
 19
References 
1. Haque, T. et al. Allogeneic cytotoxic T-cell therapy for EBV-positive posttransplantation 
lymphoproliferative disease: results of a phase 2 multicenter clinical trial. Blood 110, 1123-
1131 (2007). 
2. Einsele, H. et al. Infusion of cytomegalovirus (CMV)-specific T cells for the treatment of 
CMV infection not responding to antiviral chemotherapy. Blood 99, 3916-3922 (2002). 
3. Dudley, M.E. et al. Cancer regression and autoimmunity in patients after clonal repopulation 
with antitumor lymphocytes. Science 298, 850-854 (2002). 
4. Bollard, C.M. et al. Cytotoxic T lymphocyte therapy for Epstein-Barr virus+ Hodgkin's 
disease. J Exp Med 200, 1623-1633 (2004). 
5. Mami-Chouaib, F., Echchakir, H., Dorothee, G., Vergnon, I. & Chouaib, S. Antitumor 
cytotoxic T-lymphocyte response in human lung carcinoma: identification of a tumor-
associated antigen. Immunol Rev 188, 114-121 (2002). 
6. Van Der Bruggen, P. et al. Tumor-specific shared antigenic peptides recognized by human T 
cells. Immunol Rev 188, 51-64 (2002). 
7. Van den Eynde, B.J. & Boon, T. Tumor antigens recognized by T lymphocytes. Int J Clin 
Lab Res 27, 81-86 (1997). 
8. Kim, J.V., Latouche, J.B., Riviere, I. & Sadelain, M. The ABCs of artificial antigen 
presentation. Nat Biotechnol 22, 403-410 (2004). 
9. Figdor, C.G., de Vries, I.J., Lesterhuis, W.J. & Melief, C.J. Dendritic cell immunotherapy: 
mapping the way. Nat Med 10, 475-480 (2004). 
10. Maus, M.V. et al. Ex vivo expansion of polyclonal and antigen-specific cytotoxic T 
lymphocytes by artificial APCs expressing ligands for the T-cell receptor, CD28 and 4-1BB. 
Nat Biotechnol 20, 143-148 (2002). 
11. Suhoski, M.M. et al. Engineering artificial antigen-presenting cells to express a diverse array 
of co-stimulatory molecules. Mol Ther 15, 981-988 (2007). 
12. Sasawatari, S. et al. Efficient priming and expansion of antigen-specific CD8+ T cells by a 
novel cell-based artificial APC. Immunol Cell Biol 84, 512-521 (2006). 
13. Hirano, N. et al. Efficient presentation of naturally processed HLA class I peptides by 
artificial antigen-presenting cells for the generation of effective antitumor responses. Clin 
Cancer Res 12, 2967-2975 (2006). 
14. Dupont, J., Latouche, J.B., Ma, C. & Sadelain, M. Artificial antigen-presenting cells 
transduced with telomerase efficiently expand epitope-specific, human leukocyte antigen-
restricted cytotoxic T cells. Cancer Res 65, 5417-5427 (2005). 
15. Schilbach, K. et al. Cytotoxic minor histocompatibility antigen HA-1-specific CD8+ 
effector memory T cells: artificial APCs pave the way for clinical application by potent 
primary in vitro induction. Blood 106, 144-149 (2005). 
16. Thomas, A.K., Maus, M.V., Shalaby, W.S., June, C.H. & Riley, J.L. A cell-based artificial 
antigen-presenting cell coated with anti-CD3 and CD28 antibodies enables rapid expansion 
and long-term growth of CD4 T lymphocytes. Clin Immunol 105, 259-272 (2002). 
17. Derdak, S.V. et al. Direct stimulation of T lymphocytes by immunosomes: virus-like 
particles decorated with T cell receptor/CD3 ligands plus costimulatory molecules. Proc 
Natl Acad Sci U S A 103, 13144-13149 (2006). 
18. Rudolf, D. et al. Potent costimulation of human CD8 T cells by anti-4-1BB and anti-CD28 
on synthetic artificial antigen presenting cells. Cancer Immunol Immunother (2007). 
19. Butler, M.O. et al. Long-lived antitumor CD8+ lymphocytes for adoptive therapy generated 
using an artificial antigen-presenting cell. Clin Cancer Res 13, 1857-1867 (2007). 
20. Oelke, M. & Schneck, J.P. HLA-Ig-based artificial antigen-presenting cells: setting the 
terms of engagement. Clin Immunol 110, 243-251 (2004). 
N
at
ur
e 
Pr
ec
ed
in
gs
 : 
hd
l:1
01
01
/n
pr
e.
20
07
.1
25
0.
1 
: P
os
te
d 
24
 O
ct
 2
00
7
 20
21. Oelke, M. et al. Ex vivo induction and expansion of antigen-specific cytotoxic T cells by 
HLA-Ig-coated artificial antigen-presenting cells. Nat Med 9, 619-624 (2003). 
22. Laport, G.G. et al. Adoptive transfer of costimulated T cells induces lymphocytosis in 
patients with relapsed/refractory non-Hodgkin lymphoma following CD34+-selected 
hematopoietic cell transplantation. Blood 102, 2004-2013 (2003). 
23. Thompson, J.A., Figlin, R.A., Sifri-Steele, C., Berenson, R.J. & Frohlich, M.W. A phase I 
trial of CD3/CD28-activated T cells (Xcellerated T cells) and interleukin-2 in patients with 
metastatic renal cell carcinoma. Clin Cancer Res 9, 3562-3570 (2003). 
24. Levine, B.L. et al. Effects of CD28 costimulation on long-term proliferation of CD4+ T 
cells in the absence of exogenous feeder cells. J Immunol 159, 5921-5930 (1997). 
25. Laux, I. et al. Response differences between human CD4(+) and CD8(+) T-cells during 
CD28 costimulation: implications for immune cell-based therapies and studies related to the 
expansion of double-positive T-cells during aging. Clin Immunol 96, 187-197 (2000). 
26. Grakoui, A. et al. The immunological synapse: a molecular machine controlling T cell 
activation. Science 285, 221-227 (1999). 
27. Dustin, M.L. Stop and go traffic to tune T cell responses. Immunity 21, 305-314 (2004). 
28. Anderson, H.A., Hiltbold, E.M. & Roche, P.A. Concentration of MHC class II molecules in 
lipid rafts facilitates antigen presentation. Nat Immunol 1, 156-162 (2000). 
29. Vogt, A.B., Spindeldreher, S. & Kropshofer, H. Clustering of MHC-peptide complexes prior 
to their engagement in the immunological synapse: lipid raft and tetraspan microdomains. 
Immunol Rev 189, 136-151 (2002). 
30. Giannoni, F. et al. Clustering of T cell ligands on artificial APC membranes influences T 
cell activation and protein kinase C theta translocation to the T cell plasma membrane. J 
Immunol 174, 3204-3211 (2005). 
31. Prakken, B. et al. Artificial antigen-presenting cells as a tool to exploit the immune 
'synapse'. Nat Med 6, 1406-1410 (2000). 
32. Prakken, B.J. et al. Epitope-specific immunotherapy induces immune deviation of 
proinflammatory T cells in rheumatoid arthritis. Proc Natl Acad Sci U S A 101, 4228-4233 
(2004). 
33. Valmori, D. et al. Enhanced generation of specific tumor-reactive CTL in vitro by selected 
Melan-A/MART-1 immunodominant peptide analogues. J Immunol 160, 1750-1758 (1998). 
34. Kawakami, Y. et al. Identification of the immunodominant peptides of the MART-1 human 
melanoma antigen recognized by the majority of HLA-A2-restricted tumor infiltrating 
lymphocytes. J Exp Med 180, 347-352 (1994). 
35. Anichini, A. et al. An expanded peripheral T cell population to a cytotoxic T lymphocyte 
(CTL)-defined, melanocyte-specific antigen in metastatic melanoma patients impacts on 
generation of peptide-specific CTLs but does not overcome tumor escape from immune 
surveillance in metastatic lesions. J Exp Med 190, 651-667 (1999). 
36. Anichini, A. et al. Skewed T-cell differentiation in patients with indolent non-Hodgkin 
lymphoma reversed by ex vivo T-cell culture with gammac cytokines. Blood 107, 602-609 
(2006). 
37. Walker, M.R. et al. Induction of FoxP3 and acquisition of T regulatory activity by 
stimulated human CD4+CD25- T cells. J Clin Invest 112, 1437-1443 (2003). 
38. Zhou, J. et al. Telomere length of transferred lymphocytes correlates with in vivo 
persistence and tumor regression in melanoma patients receiving cell transfer therapy. J 
Immunol 175, 7046-7052 (2005). 
39. Klebanoff, C.A. et al. Central memory self/tumor-reactive CD8+ T cells confer superior 
antitumor immunity compared with effector memory T cells. Proc Natl Acad Sci U S A 102, 
9571-9576 (2005). 
N
at
ur
e 
Pr
ec
ed
in
gs
 : 
hd
l:1
01
01
/n
pr
e.
20
07
.1
25
0.
1 
: P
os
te
d 
24
 O
ct
 2
00
7
 21
40. Gattinoni, L. et al. Acquisition of full effector function in vitro paradoxically impairs the in 
vivo antitumor efficacy of adoptively transferred CD8+ T cells. J Clin Invest 115, 1616-
1626 (2005). 
41. Lanzavecchia, A. & Sallusto, F. Progressive differentiation and selection of the fittest in the 
immune response. Nat Rev Immunol 2, 982-987 (2002). 
42. Yee, C. et al. Adoptive T cell therapy using antigen-specific CD8+ T cell clones for the 
treatment of patients with metastatic melanoma: in vivo persistence, migration, and 
antitumor effect of transferred T cells. Proc Natl Acad Sci U S A 99, 16168-16173 (2002). 
43. Berner, V. et al. IFN-gamma mediates CD4+ T-cell loss and impairs secondary antitumor 
responses after successful initial immunotherapy. Nat Med 13, 354-360 (2007). 
44. Hamilton, S.E., Wolkers, M.C., Schoenberger, S.P. & Jameson, S.C. The generation of 
protective memory-like CD8+ T cells during homeostatic proliferation requires CD4+ T 
cells. Nat Immunol 7, 475-481 (2006). 
45. Janssen, E.M. et al. CD4+ T cells are required for secondary expansion and memory in 
CD8+ T lymphocytes. Nature 421, 852-856 (2003). 
46. Sakaguchi, S. Naturally arising Foxp3-expressing CD25+CD4+ regulatory T cells in 
immunological tolerance to self and non-self. Nat Immunol 6, 345-352 (2005). 
47. Antony, P.A. & Restifo, N.P. CD4+CD25+ T regulatory cells, immunotherapy of cancer, 
and interleukin-2. J Immunother (1997) 28, 120-128 (2005). 
48. Bocchia, M. et al. Antitumor vaccination: where we stand. Haematologica 85, 1172-1206 
(2000). 
49. Rosenberg, S.A. & Dudley, M.E. Cancer regression in patients with metastatic melanoma 
after the transfer of autologous antitumor lymphocytes. Proc Natl Acad Sci U S A 101 Suppl 
2, 14639-14645 (2004). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
N
at
ur
e 
Pr
ec
ed
in
gs
 : 
hd
l:1
01
01
/n
pr
e.
20
07
.1
25
0.
1 
: P
os
te
d 
24
 O
ct
 2
00
7
 22
 
Figure Legends 
 
Figure 1: Structures of artificial systems compared for T cell expansion efficiency. (A) 
Representation of MD structure loaded on aAPCs (adapted from Giannoni F. et al.30). GM1 
ganglioside is part of the lipid bilayer and binds one molecule of biotinylated CTB. In each MD, 
one molecule of NA anchors the biotinylated molecules to the aAPC surface through one 
biotinylated CTB.  The three free valences of NA have been saturated with anti-CD3 and anti-CD28 
and anti-hLFA-1 triggering antibodies. (B) Schematic representation of CD3/CD28 T cell expander 
dynabeads. Anti-CD3 and anti-CD28 triggering mAbs on immunomagnetic beads can interact with 
the cognate molecules on T cells, activating them. The involved molecules at the site of interaction 
can cluster exclusively on T cells. (C) Schematic representation of mouse-antihuman CD3 mAb 
(OKT3 clone) cross-linking through anti-mouse IgG on the plate bottom. Anti-CD3 mAbs are 
linked through their Fc domains to the anti-mouse IgG mAbs. The exposed anti-CD3 mAb Fab 
domains can interact with the cognate molecules on T cells, activating them. The involved 
molecules at the site of interaction can cluster exclusively on T cells.   
 
Figure 2: Activity of complete aAPCs compared to their single components. Expansion fold 
increase of purified polyclonal CD3+ T cells 14 days after stimulation with aAPC or MDs or 
liposomes, starting from 0.05 x 106 T cells freshly isolated from healthy donor PB for each 
condition. LD IL-2, or IL-15 alone, or the combination of both with HD IL-2 was added in culture. 
Cellular fold increase was evaluated by Tripan Blue dye exclusion test on days 7 and 14 of 
expansion. Results are representative of four experiments with different donors. Error bars indicate 
standard deviation (s.d.) of the mean. Statistically significant differences, calculated using two-
tailed T test, are reported (*: P≤ 0.05; ***: P≤ 0.01). 
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Figure 3: Activity of aAPCs compared to commercial artificial systems. (A) Expansion fold 
increase of polyclonal CD3+ T cells, purified from healthy donors, stimulated with aAPCs or 
immobilized anti-CD3 or anti-CD3/-CD28 microbeads. Fifty thousand T cells freshly isolated from 
healthy donor PB were cultured with one of the three artificial systems and with LD IL-2, or IL-15 
alone, or the combination of both with HD IL-2. Cellular fold increase was evaluated by Tripan 
Blue dye exclusion test on days 7 and 14 of expansion. Results are representative of four 
experiments with different donors. Error bars indicate s.d. of the mean. (B) Apoptosis assessment 
14 days after stimulating purified polyclonal CD3+ T cells with aAPCs or anti-CD3/-CD28 
microbeads or immobilized anti-CD3 plus LD IL-2, IL-15 alone or HD IL-2 and IL-15. Cytograms 
represent flow cytometric analysis of cultured cells stained with FITC-labeled ANN-V (x-axis) and 
PI (y-axis). (C) Fold increase of ANN-V-/PI- viable CD3+ T cells 2 weeks after stimulation with 
aAPC or anti-CD3/-CD28 microbeads or immobilized anti-CD3. Error bars indicate s.d. of the 
mean. P values were calculated using two-tailed T test (*: P≤ 0.05;***: P≤ 0.01). 
 
Figure 4: Phenotypic characteristics of expanded polyclonal human T cells with aAPCs or 
other artificial systems plus HD IL2 and IL 15 for 14 days. (A) Histogram representation of cell 
subset frequencies in cultures expanded with HD IL-2 plus IL-15 and aAPCs or OKT3 or anti-
CD3/-CD28 microbeads. Results are representative of four experiments with different donors. Error 
bars indicate s.d. of the mean. Statistical analyses of aAPC versus microbeads results and of aAPC 
versus immobilized anti-CD3 ones were performed using two-tailed T test (*: P≤ 0.05;**: P≤ 0.02; 
***: P≤ 0.01). (B) Representative example of T cell immunophenotype after 14-day expansion with 
aAPC stimulation and HD IL-2 plus IL-15. Multiparametric FACS analysis were performed by 
gating on CD4+ versus SSC and CD8 versus SSC populations (C) Histogram plot representation of 
intracellular expression of granzyme B (left panel) and perforin expression (right panel) in CD8+ T 
cells (upper panel), identified by gating on CD3+CD8+ T cell subset, and in CD4+T cells (lower 
panel), identified by gating on CD3+CD8- T cell subset. 
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Figure 5: Expansion of anti-MART-1 human specific T lymphocytes. (A) Expansion fold 
increase of After 2 of pre-enriched anti-MART-1 specific human T lymphocytes 14 days after 
stimulation with anti-CD3/-CD28 microbeads or immobilized anti-CD3 or our aAPCs in the 
presence of HD IL-2 and IL-15. Cellular fold increases were evaluated by Tripan Blue dye 
exclusion test on days 7 and 14 of expansion with artificial systems. X-axis, days in culture; y-axis, 
fold increase. (B) Apoptosis assessment in cultures of anti-MART-1 specific human T cells 14 days 
after stimulation with aAPCs or anti-CD3/-CD28 microbeads plus HD IL-2 and IL-15. Cytograms 
represent flow cytometric analysis of cultured cells stained with FITC-labeled ANN-V (x-axis) and 
PI (y-axis). (C) Cytotoxicity of anti-MART-1 specific human T cells after 14-day expansion from 
the stimulation with aAPCs or anti-CD3/-CD28 microbeads or immobilized anti-CD3 plus HD IL-2 
and IL-15, or with MART-1 loaded T2 cell line (T2-MART-1) was tested by 51Cr release assay 
using LCL target cells pulsed with the specific MART-1 antigen. Specific activity was measured 
from the difference between the lysis of LCL presenting the cognate tumor antigen and the lysis of 
LCL alone or loaded with the unrelated Flu or HIV peptides. Results are representative of three 
experiments. Error bars indicate s.d. of the mean. Statistical analyses were performed using two-
tailed T test (*: P≤ 0.05). (D) Representative example of anti-MART-1 T cell immunophenotype 2 
weeks after aAPC stimulation. Cell suspensions were analyzed by FACS, gating on CD4+CD3+, 
CD4-CD3+ (CD8 cell subset) and MART-1+CD4-CD3+ populations. Cells were analyzed for the 
expression of CD62L versus CD45RA, CD69 and of FOXP3 to define their maturation and 
activation level and regulatory T cell frequency in expanded cultures respectively. 
 
Figure 6: Effect on T cell expansion of the 1: 10 or 1: 100 aAPC dose: T cell ratios.  
Ten and 100 fold superior amount of purified polyclonal CD3+ T cells isolated from healthy donor 
PB were cultured for two weeks with the same dose of aAPCs previously used, with HD IL-2 and 
IL-15. (A) Fold increase representation of polyclonal CD3+ T cells expanded for 14 days with 
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aAPCs. Five millions or 0.5 x 106 T cells were cultured with the same dose of aAPCs used for 0.05 
x 106 starting cells and HD IL-2 plus IL-15. Cellular fold increase was evaluated by Tripan Blue 
dye exclusion test on days 7 and 14 of expansion. Results are representative of three experiments 
with different donors. Error bars indicate s.d. of the mean. (B) Maturation status defined as 
CD45RA versus CD62L expression 14 days after stimulation with 1: 10 or 1: 100 aAPC = dose: T 
cell ratio. (C) Evaluation of aAPC amount and culture volumes required to hypothetically expand 
109 cells for adoptive immunotherapy using different aAPC dose: T cell ratio. From the empirically 
found fold increase, it was possible to derive the starting cell number and the related amount of 
aAPCs required to obtain 109 T cells in the different conditions of aAPC dose: T cell ratio.  
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